Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine
Sponsor: DF/Net Rearch
This PHASE1 trial investigates Pain and is currently completed. DF/Net Rearch leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Dec 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- DF/Net Rearch
- ITT Research Institute
- PRA Health Sciences
- Syntrix Biosystems, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .